Alumni Spotlight is pleased to announce The Top 50 University Alumni in the Pharmaceuticals Industry of 2022. These individuals take part in one of the most interesting, meaningful, and life-changing fields. Their work enables products that help address some of today’s biggest challenges including an aging society, population growth, and the need to make sustainable and efficient medicines. Their research, development, and new medicines are a key asset to the global economy.
Among this year’s awardees are Bill Falstich, Vice President of Biopharma Hospital Supply of Pfizer, who is responsible for global end-to-end supply chain planning and orchestration for the company’s GEP Solid Oral Dose Products Portfolio; Kendra Rose, Vice President and Head of New Platforms, Ophthalmology, and Hemophilia at Bayer Pharmaceuticals, whose responsibilities include providing commercial input and evaluation for all pharmaceutical deals; and Tom McCubbins, Senior Vice President of Global Pharmaceutical Operations, who leads the company’s manufacturing network consisting of 15 sites located in 12 countries.
We acknowledge these individuals for their dedication to the advancement of our society’s health and wellbeing. Please join us in celebrating the accomplishments of The Top 50 University Alumni in the Pharmaceuticals Industry of 2022.
1. Teri Lawver
Worldwide Vice President of Immunology, Johnson & Johnson
Teri Lawver is the Worldwide Vice President of Immunology of Johnson & Johnson. She first joined the company in 2002 as senior director of gastroenterology marketing of Centocor. Johnson & Johnson (J&J) is a multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. It is one of the world's most valuable companies. In her role, Lawver has worldwide end-to-end responsibility for the company’s $16B+ Immunology Portfolio and Pipeline.
Lawver has more than 25 years of experience. Since joining J&J in 2002 at Centocor, she has held several leadership and executive positions across the company and has delivered an above-market performance in each of the five Johnson & Johnson business units she has led. Prior to joining Johnson & Johnson, Lawver was an associate principal at McKinsey & Company and a leader in the Firm’s Global Healthcare practice. She began her career as a derivatives analyst at Bloomberg Financial Markets, LLP. Lawver earned an MBA from Duke University - The Fuqua School of Business and an undergraduate degree from Georgetown University.
3. Michael Braun
SVP of Immunology & Fibrosis, Bristol Myers Squibb
University of Michigan
Michael Braun is the Senior Vice President of Immunology and Fibrosis for Bristol Myers Squibb. He first joined the company in 2022. At Bristol Myers Squibb, they work every day to transform patients’ lives through science. They have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how they can best deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Braun has nearly 23 years of experience. He began his career in 1999.
Before joining Bristol Myers Squibb, Braun was a VP and head of immunology, hepatology, and dermatology at Novartis, and before that, a senior manager of targeting and alignments at Pharmacia. Earlier in his career he worked with ZS Associates as a business associate. Braun graduated from the University of Michigan with an undergraduate degree in economics.
4. Kendra Rose
VP & Head of New Business Development, Bayer Pharmaceuticals
Kendra Rose began her professional career 24 years ago. Today, she is the Vice President and Head of New Platforms, Ophthalmology and Hemophilia at Bayer Pharmaceuticals. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, it aims to create value through innovation, growth, and high earning power. Its products help address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient and sustainable use of natural resources.
Rose first got her start in 1998 as a senior scientist at Johnson & Johnson. From there, she went on to Cordis Corp, before eventually rising to become the global brand director of Entresto at Novartis, her most recent position prior to joining Bayer Pharmaceuticals. Rose graduated from Stanford University with a PhD in chemistry, from The Wharton School with an MBA in marketing and operations, and from Ohio Wesleyan University with an undergraduate degree in chemistry.
5. Paul Rowe
VP & Head of Global Medical Immunology, Sanofi
Paul Rowe is the Vice President and Head of Global Medical of Immunology of Sanofi. He first joined the company in 2015. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. In his role, Rowe is responsible for the management and supervision of the Global Medical Immunology Franchise primarily encompassing respiratory, rheumatology, and dermatology and other related therapeutic areas and sub-specialties. He provides oversight of overall Immunology Franchise medical strategy encompassing key areas across medical education, communication, engagement, and late phase clinical trial data generation activities. Rowe has over a decade of research experience spanning from preclinical to late phase drug development programs, primarily in respiratory medicine, at several large pharma companies.
Previously, Rowe was a senior medical director of medical research & strategy at Daiichi Sankyo where he served as senior physician responsible on the therapy brand team and led medical teams in pre-launch, launch, and post-launch functions and activities. Before that, Rowe was a director of clinical development for respiratory at Forest Research Institute. Earlier in his career he worked with Boehringer Ingelheim Pharmaceuticals in medical affairs for national medicine and field-based medicine. Rowe has authored and co-authored several publications in respiratory medicine (COPD) and is a frequent lecturer and speaker at professional society meetings, and educational forums. He is an active committee member of several national and international respiratory societies including the American Thoracic Society and European Respiratory Society and has a primary interest in promoting scientific research collaboration across government, academia, and industry. Dr. Rowe holds degrees and certification from Harvard University, the University of Rochester School of Medicine, Villanova University, and the London School of Economics.
6. Duke Fitch
VP of Pharmaceutical Patents, GSK
Duke Fitch began his professional career 22 years ago. Today, he is the Vice President of Pharmaceutical Patents of GSK. GSK is a multinational pharmaceutical company with global headquarters in London, England. It prioritizes innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is its R&D focus on the science of the immune system, human genetics and advanced technologies, and its world-leading capabilities in vaccine and medicines development. GSK focuses on four therapeutic areas including infectious diseases, HIV, oncology, and immunology including respiratory diseases. It aims to impact the health of 2.5 billion people over the next 10 years. Its bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
Fitch graduated from Temple University - James E. Beasley School of Law with a JD, from Harvard University with a PhD in organic chemistry, and from the University of Pennsylvania with an undergraduate degree in chemistry.
8. Stephen Lin
Chief Safety Officer, SVP, & Head of Global Pharmacovigilance, Sanofi
The Johns Hopkins University
Stephen Lin is the Chief Safety Officer, Senior Vice President, and Head of Global Pharmacovigilance of Sanofi. Sanofi is an innovative global healthcare company headquartered in Paris, France. It engages in the research and development, manufacturing, and marketing of pharmaceutical drugs principally in the prescription market, but also with over-the-counter medication. The corporation covers seven major therapeutic areas including cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur). Lin is a biopharmaceutical industry senior executive with several years of experience in strategic planning, pharmacovigilance, R&D, and medical affairs.
Before joining Sanofi, Lin worked within the safety planning, evaluation, and reporting team at PhRMA. Earlier in his career he worked with Sanofi-Aventis Pharmaceuticals as an associate director of pharmacovigilance. Lin graduated from The George Washington University School of Medicine and Health Sciences with an MD, and from The Johns Hopkins University with an undergraduate degree in biology.
10. Gerard O'Malley
VP & Global Franchise Head, AstraZeneca
University of Pennsylvania
Gerard O'Malley is a Vice President and Global Franchise Head of AstraZeneca. He first joined the company in 1999 as group product director of respiratory and inflammation. AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Its purpose is to push the boundaries of science to deliver life-changing medicines. It focuses on three main therapy areas including oncology, cardiovascular and metabolic disease, and respiratory, and it is also selectively active in the areas of autoimmunity, neuroscience, and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Previously, O'Malley was a global project manager at Rhone-Poulenc Rorer, and before that, an international project manager at Hoechst Roussel Pharmaceuticals. Earlier in his career he worked with Hoechst AG as an exchange scientist. O'Malley earned a PhD in organic chemistry from the University of Pennsylvania, an MBA in marketing from Rider University, and an undergraduate degree in chemistry from The College of New Jersey.
View the complete list of awardees.
12. Ding Ming
SVP & GM of China Operations, Clinical Research Group of Thermo Fisher Scientific
University of Wisconsin-Madison
Ding Ming is the Senior Vice President and General Manager of China Operations at the Clinical Research Group of Thermo Fisher Scientific. Thermo Fisher Scientific is the world leader in serving science, with annual revenue of approximately $40 billion. Its mission is to enable its customers to make the world healthier, cleaner, and safer. Ming is a trained chief executive with 20+ years of global pharmaceutical leadership experience in strategy, organization, and operations to innovate drug, medical device, diagnostics, biologics, and other therapeutic products.
Ming first got his start in 1997 as an associate director of medical nutrition at Novartis. From there, he went on to Pfizer, before eventually rising to become a VP and general manager of China operations at PPD, his most recent position prior to joining Thermo Fisher Scientific. Ming graduated from the University of Wisconsin-Madison with a PhD in animal health and biomedical sciences.
13. Eric Blomme
VP of Development Biological Sciences, AbbVie
The Ohio State University
Eric Blomme is the Vice President of Development Biological Sciences of AbbVie. He first joined the company in 2013 as director of integrative pharmacology, investigative toxicology, and pathology. Originated as a spin-off of Abbott Laboratories, AbbVie is a publicly traded biopharmaceutical company founded in 2013. Its mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. It strives to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience, eye care, virology, women’s health, and gastroenterology.
Previously, Blomme was a director of investigative toxicology and pathology at Abbott. Earlier in his career he worked with Pharmacia as a pathologist. Blomme earned a PhD in veterinary pathology and pathobiology from The Ohio State University and an undergraduate degree from McGill University.
16. Daniel Asch
VP of Oncology, Boehringer Ingelheim
Daniel Asch began his professional career nearly 29 years ago. Today, he is the Vice President of Oncology for Boehringer Ingelheim. Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. It is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, it creates value through innovation in areas of high unmet medical need. In his roles, Asch leads a commercial team of 70 people including sales, national accounts, and marketing teams.
Asch first got his start in 1993 as a product manager at Forest Pharmaceuticals. From there, he went on to Sanofi, before eventually rising to become a general manager at Eisai Limited - Canada, his most recent position prior to joining Boehringer Ingelheim. Asch graduated from Columbia Business School with an MBA and from Duke University with an undergraduate degree in marketing management.
19. Lee James
VP of US Medical Oncology, Bristol Myers Squibb
Lee James is the Vice President of US Medical Oncology of Bristol Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. In his role, James’ goal is to improve both the quantity and quality of life of patients with cancer by helping bridge the gap between basic science and clinical medicine. He has over 20 years of experience. He began his career in 2002.
Before joining Bristol Myers Squibb, James was an asset team lead of oncology late phase strategy and development at Pfizer, and before that, a medical oncologist and hematologist at Queens Medical Associates, PC. Earlier in his career he served with the University of Chicago Hospitals as a resident. James graduated from the University of Washington with a PhD in molecular and cellular biology, from the University of Washington - School of Medicine with an MD, and from Cornell University with an undergraduate degree in microbiology.
21. Elyse Newton
VP & Head of Pharmaceutical Sciences Operations & Partnerships, Takeda
Elyse Newton is the Vice President and Head of Pharmaceutical Sciences Operations & Partnerships for Takeda. Takeda is a research-based global company with its main focus on pharmaceuticals for metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. As the largest pharmaceutical company in Asia, and one of the top 20 largest pharmaceutical companies in the world by revenue, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide. Newton has 27 years of experience. She began her career in 1995.
Before joining Takeda, Newton was the head of operations of global oncology at Genzyme, and before that, an associate director at Biogen. Earlier in her career she worked with Associated Industries of Massachusetts as a research associate. Newton graduated from the University of Michigan Business School with an MBA and from Dartmouth College with an undergraduate degree in economics.
26. Brian McCormick
VP, Chief Regulatory Counsel & Head of Global Regulatory Policy, Teva Pharmaceuticals
Brian McCormick is the Vice President, Chief Regulatory Counsel and Head of Global Regulatory Policy of Teva Pharmaceuticals, the global leader in generic medicine. Teva has been developing and producing medicines to help improve people’s lives for more than a century. Around 200 million people around the world take a Teva medicine every day. Along with the company’s established presence in generics, it has significant innovative research and operations supporting its growing portfolio of specialty and biopharmaceutical products. McCormick is a skilled regulatory and policy lawyer with 20 years of experience counseling research-based, specialty, and generic pharmaceutical firms, as well as innovative biotechnology and biosimilar businesses.
McCormick was previously a partner in the pharmaceutical/biotechnology practice of a leading firm. He graduated from Georgetown University Law Center with a JD, from The Johns Hopkins University School of Public Health with an MHS in health policy, and from Franklin & Marshall College with an undergraduate degree in government and history.
29. Christopher Calabretta
VP of Supply Chain, Ancillare
Penn State University
Christopher Calabretta is the Vice President of Supply Chain of Ancillare. Since 2006, Ancillare has driven the creation and innovation of the Clinical Trial Ancillary Supply Chain (CTASC™), proving that well-planned clinical supply chains can help accelerate approvals of life-saving therapies for patients. Calabretta is a proven strategic business leader specializing in global supply chain, procurement, and operations. His vast experience lies heavily in supply chain management, direct and indirect procurement, manufacturing operations and ancillary clinical trial management across the pharmaceutical, medical device, consumer health products. Calabretta has over 32 years of experience. He began his career in 1990.
Before joining Ancillare, Calabretta was a VP of global indirect procurement at CommScope, and before that, a VP of global indirect procurement at Campbell Soup Company. Earlier in his career he worked with PepsiCo as a shipping supervisor. Calabretta graduated from Villanova University with an MBA and from Penn State University with an undergraduate degree in business logistics.
View the complete list of awardees.
31. Gary Herman
SVP of Early Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals
Gary Herman is an intuitive, collaborative scientist with extensive experience in leading early clinical and translational medicine functions across all therapeutic areas. He currently serves as the Senior Vice President of Early Clinical Development & Experimental Sciences of Regeneron Pharmaceuticals. Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in its laboratories. The company’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases, and rare diseases. Herman has 34 years of experience. He began his career in 1988.
Before joining Regeneron Pharmaceuticals, Herman was a VP and head of early-stage development at Merck. Earlier in his career he worked with the University of California, San Francisco as a pediatric resident. Herman graduated from Harvard Medical School with an MD and from the University of California, San Diego with an undergraduate degree in biochemistry and cell biology.
33. Adrian Looney
VP & Chief Intellectual Property Counsel, Vertex Pharmaceuticals
Columbia University in the City of New York
Adrian Looney is a Vice President and Chief Intellectual Property Counsel at Vertex Phamaceutical's Assistant world headquarters in Boston. He leads a team of patent attorneys and professional staffers who provide IP support for the cystic fibrosis franchise with 4 commercial products. The areas of therapeutic focus are cystic fibrosis, pain, kidney diseases, sickle cell disease, duchenne muscular dystrophy, and type I diabetes.
Prior to joining Vertex. Looney worked as an IP leader at Pfizer in New York City. Previous to Pfizer, he was a patent agent and associate at two New York based intellectual property law firms where his practice focused on the procurement of patents, client consulting, due diligence and litigation for universities, biopharmaceutical and pharmaceutical clients. Looney is a registered patent attorney with the U.S. Patent and Trademark Office and is a member of the State Bar of New York. He received his JD degree from New York Law School, a MA, MPhil, and PhD in chemistry from Columbia University and an honors undergraduate degree in chemistry from University College Cork, Ireland.
34. John Joyal
VP of Biological Science, Moderna Therapeutics
John Joyal is the Vice President of Biological Science of Moderna Therapeutics. He first joined the company in 2013. Moderna is a pharmaceutical and biotechnology company that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to produce an immune response. mRNA is not new technology, but Moderna is discovering new ways to use it to treat and prevent infectious, immuno-oncology, and cardiovascular diseases. mRNA medicines fight diseases in a different way than traditional medicine by prompting immune systems to create the tools to treat or prevent disease. Since its founding in 2010, the company has worked to build the industry's leading mRNA technology platform.
Previously, Joyal was a VP of discovery research at Molecular Insight Pharmaceuticals, and before that, a director of discovery research at Phylogix. Earlier in his career he worked with Praecis Pharmaceuticals as a director of cell biology. Joyal earned a PhD in biology from Tufts University.
38. Mary Beth McNerney
VP of Sales, Xeris Pharmaceuticals
Mary Beth McNerney is the Vice President of Sales of Xeris Pharmaceuticals. She first joined the company in 2017 as senior director of marketing. Headquartered in Chicago, Xeris Pharmaceuticals is a specialty pharmaceutical company that leverages novel formulation technology platforms to develop and commercialize ready-to-use liquid-stable injectables. The company is focused on creating medicines that are easier to use, including its Gvoke® glucagon injection.
Previously, McNerney was a director of market development and competitive strategies at Shire. Earlier in her career she worked with Baxter International as an associate director of marketing in immunology. McNerney earned an MBA from Northwestern University - Kellogg School of Management and an undergraduate degree in government from Harvard University.
39. Elizabeth Powell
Chief Compliance Officer & Head of Legal of Rare Disease, ANI Pharmaceuticals, Inc.
Elizabeth Powell began her professional career 32 years ago. Today, she is the Chief Compliance Officer and Head of Legal for ANI Pharmaceuticals. ANI is an integrated specialty pharmaceutical company focused on delivering value to its customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. It focuses on niche and high barriers to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its two pharmaceutical manufacturing facilities are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully contained environment.
Powell first got her start in 1990 as an associate at Morgan, Lewis & Bockius LLP before eventually rising to become a managing counsel and executive director of U.S. commercial & compliance at Merck. Powell graduated from the University of Wisconsin Law School with a JD and from Stanford University with an undergraduate degree in political science and government.
43. Dannielle Appelhans
Chief Operating Officer, Rubius Therapeutics
Massachusetts Institute of Technology
Dannielle Appelhans is the Chief Operating Officer of Rubius Therapeutics. She first joined the company in 2021. Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Its proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them into cellular medicines. With the company’s deep scientific know-how and dedicated team, it is focused on making its vision a reality, creating life-changing cellular therapies for patients with cancer and autoimmune diseases.
Previously, Appelhans was an SVP of technical operations and CTO at Novartis Gene Therapies, and before that, a global head of technical operations at Sandoz. Earlier in her career she worked with Eli Lilly and Company as a process engineer in lyophilization. Appelhans earned an MBA and an MS in mechanical engineering from Massachusetts Institute of Technology, and an undergraduate degree in mechanical engineering from the University of Michigan.
44. Brian Schwartz
VP of Clinical Development, Chinook Therapeutics
University of Pennsylvania
Brian Schwartz is the Vice President of Clinical Development of Chinook Therapeutics. Chinook is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Its product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a treatment for IgA nephropathy and other proteinuric glomerular diseases. In addition, the company is advancing CHK-336, a treatment for primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. Schwartz has 21 years of experience. He began his career in 2001.
Before joining Chinook, Schwartz was a senior medical director of clinical development at Corbus Pharmaceuticals, and before that, a senior medical director of clinical development at Akebia Therapeutics. Earlier in his career he worked with Pfizer Pharmaceuticals as a director and research specialist in cardiovascular area. Schwartz graduated from Babson F.W. Olin Graduate School of Business with an MBA and from the University of Pennsylvania with an undergraduate degree in biochemistry.
View the complete list of awardees.
46. Taylor Sandison
Chief Medical Officer, Cidara Therapeutics
Taylor Sandison began his professional career nearly 29 years ago. Today, he is the Chief Medical Officer of Cidara Therapeutics. Cidara is a clinical stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives.
Sandison first got his start in 1993 as a researcher at Howard Hughes Medical Institute. From there, he went on to The International School of Kuala Lumpur, before eventually rising to become a senior medical director at Merck, his most recent position prior to joining Cidara Therapeutics. Sandison graduated from the University of Washington with an MD and an MPH in epidemiology of infectious diseases, and from Dartmouth College with an undergraduate degree in biochemistry.
48. Arthur Chan
VP of Medical Affairs, Tarsus Pharmaceuticals
University of Washington
Arthur Chan is the Vice President of Medical Affairs of Tarsus Pharmaceuticals. Tarsus is a biopharmaceutical company that aims to bring novel therapeutics to patients across a range of diseases with limited treatment options. They operate at the highest standard of integrity and are uncompromising in dedication to science and disease understanding. Chan is an innovative and creative medical affairs executive leader with 18+ years of industry experience in diverse therapeutic areas, specializing in ophthalmology.
Chan first got his start in 2001 as a product development engineer at EKOS Corporation. From there, he went on to INSIGHTEC before eventually rising to become a lead medical director of eye care at Novartis, his most recent position prior to joining Tarsus Pharmaceuticals. Chan graduated from the University of Washington with a PhD in bioengineering, from Saint Joseph's University with an MBA, and from the University of Alberta with an undergraduate degree in mechanical engineering.
49. Thomas Templeman
Chief Technology Officer, Centessa Pharmaceuticals
Thomas Templeman began his professional career over 33 years ago. Today, he is the Chief Technology Officer of Centessa Pharmaceuticals. Contessa is a clinical-stage pharmaceutical company with a R&D innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients. Its programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. Centessa is led by a management team with extensive R&D experience, providing direct guidance to its program teams to rapidly advance its candidates from research through all stages of development.
Templeman first got his start in 1989 as a senior scientist at MilliGen. From there, he went on to Axovant Sciences, before eventually rising to become an SVP of pharmaceutical operations and quality at Nuvation Bio, his most recent position prior to joining Centessa Pharmaceuticals. Templeman graduated from Dartmouth College with a PhD in biology and from Santa Clara University with an undergraduate degree in biology.
View the complete list of awardees.